RVNC - Revance Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.73
-1.34 (-5.81%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close23.07
Open23.22
Bid0.00 x 800
Ask37.00 x 800
Day's Range21.68 - 23.26
52 Week Range19.62 - 37.45
Volume317,412
Avg. Volume274,588
Market Cap803.743M
Beta (3Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-3.95
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.38
Trade prices are not sourced from all markets
  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics

    NEW YORK, NY / ACCESSWIRE / December 5, 2018 / Shares of Novelion Therapeutics and Revance Therapeutics were both soaring on Tuesday on separate developments. Novelion saw gains as it was revealed that biotech focused venture capital firm Healthcare Value Capital sent a letter demanding exploration of strategic alternatives, while Revance Therapeutics soared on news that its Botox rival succeeds in late-stage trial and that it had reached an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Novelion Therapeutics Inc. shares were up 32.65% yesterday at the close on almost 17.5 million shares traded.

  • MarketWatch8 days ago

    Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002

    Shares of Revance Therapeutics Inc. were up 1.9% in premarket trade Tuesday after the company announced it had entered an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. to give Fosun exclusive rights to develop and commercialize Revance's botulinum toxin formulation RT002 in mainland China, Hong Kong and Macau. Under the licensing agreement, Revance will receive an upfront payment of $30 million and is eligible to receive up to an additional $230.5 million in future development and sales milestone payments, as well as royalties on future net sales. Shares of Revance have fallen 42% in the year to date, while the iShares Nasdaq Biotechnology exchange traded fund has gained 3.3%. The SPDR S&P Biotech ETF, which includes smaller biotech companies, has fallen 0.3%, and the S&P 500 has advanced 4.4%.

  • Reuters8 days ago

    Revance Therapeutics' Botox rival succeeds in late-stage trial

    A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year. More than 95 percent of patients administered with Revance's long-acting neuromodulator injection RT002 were found to have none or mild frown lines after four weeks, according to data from the third late-stage study. The treatment, which requires two or less doses a year, was effective in maintaining reduced wrinkle severity in patients for a median duration of 24 weeks.

  • Business Wire8 days ago

    Revance Announces China Market License Agreement with Fosun Pharma for RT002

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma), providing Fosun Pharma Industrial with the exclusive rights to develop and commercialize Revance’s proprietary DaxibotulinumtoxinA for Injection (RT002) in mainland China, Hong Kong and Macau (the Territory). RT002 is a novel, long-lasting neuromodulator in development for the treatment of aesthetic conditions, including glabellar and upper facial lines, and neuroscience conditions including cervical dystonia, plantar fasciitis, adult upper limb spasticity and chronic migraine.

  • Business Wire8 days ago

    Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate-to-severe glabellar (frown) lines in the SAKURA 3 Phase 3 open-label, long-term safety study. As a component of the largest clinical program of an aesthetic neuromodulator, the SAKURA 3 study included nearly 2,700 patients and more than 3,800 treatments.

  • GlobeNewswire15 days ago

    Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire22 days ago

    Revance to Participate in Upcoming Investor Conferences

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences. President and Chief Executive Officer, Dan Browne, is scheduled to participate in a fireside discussion at the Evercore ISI, HealthCONx in Boston, MA on Tuesday, November 27 at 4:15pm ET. President and Chief Executive Officer, Dan Browne, is also scheduled to participate in a fireside discussion at the Piper Jaffray 30th Annual Healthcare Conference in New York, NY on Wednesday, November 28 at 12:30pm ET.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of RVNC earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Revance Therapeutics Inc Earnings Call

  • Why Revance Therapeutics Inc’s (NASDAQ:RVNC) CEO Pay Matters To You
    Simply Wall St.27 days ago

    Why Revance Therapeutics Inc’s (NASDAQ:RVNC) CEO Pay Matters To You

    Dan Browne has been the CEO of Revance Therapeutics Inc (NASDAQ:RVNC) since 2002. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...

  • Business Wirelast month

    Revance to Participate in the Credit Suisse Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare Conference in Phoenix, AZ.

  • Business Wirelast month

    Revance Releases Third Quarter 2018 Results

    - Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 -

  • Business Wire2 months ago

    Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quarter 2018 financial results on Thursday, November 1, 2018 after the close of market. Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C. Schilke as chief financial officer, effective November 5th. Mr. Schilke will report to Dan Browne, president and chief executive officer. “Toby is a great steward of financial integrity, bringing significant value and global business insights.

  • Business Wire3 months ago

    Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY. President and Chief Executive Officer, Dan Browne, is scheduled to present on Tuesday, October 2 at 11:30am ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com.

  • Business Wire3 months ago

    Revance Receives Great Place to Work Certification

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company was certified as a great workplace this month by the independent analysts at Great Place to Work®. “As a biotech company on the cusp of our first product launch, we’ve worked through the long, challenging drug development process to build a company dedicated to its people and its mission to be a leader of innovation in neuromodulators. Great Place to Work is a global research, consulting and training firm that helps organizations create and sustain great workplaces through the development of high-trust workplace cultures.

  • Before You Buy Revance Therapeutics Inc’s (NASDAQ:RVNC), Consider This
    Simply Wall St.3 months ago

    Before You Buy Revance Therapeutics Inc’s (NASDAQ:RVNC), Consider This

    If you’re interested in Revance Therapeutics Inc (NASDAQ:RVNC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...

  • Benzinga3 months ago

    JMP: Changing Competitive Landscape Makes Revance Less Appealing

    Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of RVNC earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 Revance Therapeutics Inc Earnings Call

  • Business Wire4 months ago

    Revance Releases Second Quarter 2018 Results

    Revance Therapeutics, Inc. , a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018.

  • ACCESSWIRE4 months ago

    Revance Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Revance Therapeutics, Inc. (NASDAQ: RVNC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • Business Wire5 months ago

    Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018

    -Conference Call Scheduled for Thursday, August 2, 2018 at 4:30pm ET-

  • Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zacks5 months ago

    Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?

  • Cramer: Don't get your hopes up with the stock of Botox maker Allergan
    CNBC5 months ago

    Cramer: Don't get your hopes up with the stock of Botox maker Allergan

    Jim Cramer and technician Tim Collins review Allergan's stock charts to figure out what might be next for the Botox maker.